| pubmed-article:17390042 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17390042 | lifeskim:mentions | umls-concept:C0597032 | lld:lifeskim |
| pubmed-article:17390042 | lifeskim:mentions | umls-concept:C1518051 | lld:lifeskim |
| pubmed-article:17390042 | lifeskim:mentions | umls-concept:C0032207 | lld:lifeskim |
| pubmed-article:17390042 | lifeskim:mentions | umls-concept:C0312418 | lld:lifeskim |
| pubmed-article:17390042 | lifeskim:mentions | umls-concept:C0441767 | lld:lifeskim |
| pubmed-article:17390042 | lifeskim:mentions | umls-concept:C1527249 | lld:lifeskim |
| pubmed-article:17390042 | lifeskim:mentions | umls-concept:C1446468 | lld:lifeskim |
| pubmed-article:17390042 | lifeskim:mentions | umls-concept:C0036667 | lld:lifeskim |
| pubmed-article:17390042 | lifeskim:mentions | umls-concept:C0205262 | lld:lifeskim |
| pubmed-article:17390042 | lifeskim:mentions | umls-concept:C0701185 | lld:lifeskim |
| pubmed-article:17390042 | lifeskim:mentions | umls-concept:C0243072 | lld:lifeskim |
| pubmed-article:17390042 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:17390042 | pubmed:dateCreated | 2007-3-28 | lld:pubmed |
| pubmed-article:17390042 | pubmed:abstractText | Among 13 patients with recurrent colorectal cancer (recurrence group: RG), immunohistochemical expression of Topo-1 was high in 4 patients (30.8%) and low in 9 patients (69.2%), while the non-recurrence group (N-RG) (n=8) showed high expression in 1 patient (12.5%) and low expression in 7 patients (87.5%) (NS). Regarding immunohistochemical expression of Bax/ERCC-1, high Bax/low ERCC-1 expression was observed in 6 patients (46.2%) from the RG and other patterns of expression were seen in 7 patients (53.8%), while high Bax/low ERCC-1 expression was observed in 4 patients (50.0%) from the N-RG and other patterns were found in 4 patients (50.0%) (NS). PCR analysis of Topo-1 expression revealed high expression in 9 patients (75.0%) from the RG (n=12) and low expression in 3 patients (25.0%), while the N-RG (n=8) showed high expression in all 8 patients (100.0%) and low expression in none (NS). With respect to ERCC-1, PCR analysis revealed high expression in 7 patients (58.3%) from the RG (n=12) and low expression in 5 patients (41.7%), while the N-RG (n=8) showed high expression in 1 patient (12.5%) and low expression in 7 patients (87.5%) (p<0.05). These results suggest that tumor sensitivity to CPT-11 and platinum derivatives is similar in stage II colorectal cancer patients with ONCs. | lld:pubmed |
| pubmed-article:17390042 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17390042 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17390042 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17390042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17390042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17390042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17390042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17390042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17390042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17390042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17390042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17390042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17390042 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17390042 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17390042 | pubmed:month | May | lld:pubmed |
| pubmed-article:17390042 | pubmed:issn | 1021-335X | lld:pubmed |
| pubmed-article:17390042 | pubmed:author | pubmed-author:NakamuraMasat... | lld:pubmed |
| pubmed-article:17390042 | pubmed:author | pubmed-author:MukaiMasayaM | lld:pubmed |
| pubmed-article:17390042 | pubmed:author | pubmed-author:MakuuchiHiroy... | lld:pubmed |
| pubmed-article:17390042 | pubmed:author | pubmed-author:KomatsuNobuka... | lld:pubmed |
| pubmed-article:17390042 | pubmed:author | pubmed-author:NakasakiHisao... | lld:pubmed |
| pubmed-article:17390042 | pubmed:author | pubmed-author:SatoShinkichi... | lld:pubmed |
| pubmed-article:17390042 | pubmed:author | pubmed-author:MatsuiNaruaki... | lld:pubmed |
| pubmed-article:17390042 | pubmed:author | pubmed-author:NinomiyaHirom... | lld:pubmed |
| pubmed-article:17390042 | pubmed:author | pubmed-author:WakuiKanakoK | lld:pubmed |
| pubmed-article:17390042 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17390042 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:17390042 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17390042 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17390042 | pubmed:pagination | 1045-50 | lld:pubmed |
| pubmed-article:17390042 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:17390042 | pubmed:meshHeading | pubmed-meshheading:17390042... | lld:pubmed |
| pubmed-article:17390042 | pubmed:meshHeading | pubmed-meshheading:17390042... | lld:pubmed |
| pubmed-article:17390042 | pubmed:meshHeading | pubmed-meshheading:17390042... | lld:pubmed |
| pubmed-article:17390042 | pubmed:meshHeading | pubmed-meshheading:17390042... | lld:pubmed |
| pubmed-article:17390042 | pubmed:meshHeading | pubmed-meshheading:17390042... | lld:pubmed |
| pubmed-article:17390042 | pubmed:meshHeading | pubmed-meshheading:17390042... | lld:pubmed |
| pubmed-article:17390042 | pubmed:meshHeading | pubmed-meshheading:17390042... | lld:pubmed |
| pubmed-article:17390042 | pubmed:meshHeading | pubmed-meshheading:17390042... | lld:pubmed |
| pubmed-article:17390042 | pubmed:meshHeading | pubmed-meshheading:17390042... | lld:pubmed |
| pubmed-article:17390042 | pubmed:meshHeading | pubmed-meshheading:17390042... | lld:pubmed |
| pubmed-article:17390042 | pubmed:meshHeading | pubmed-meshheading:17390042... | lld:pubmed |
| pubmed-article:17390042 | pubmed:meshHeading | pubmed-meshheading:17390042... | lld:pubmed |
| pubmed-article:17390042 | pubmed:meshHeading | pubmed-meshheading:17390042... | lld:pubmed |
| pubmed-article:17390042 | pubmed:meshHeading | pubmed-meshheading:17390042... | lld:pubmed |
| pubmed-article:17390042 | pubmed:meshHeading | pubmed-meshheading:17390042... | lld:pubmed |
| pubmed-article:17390042 | pubmed:meshHeading | pubmed-meshheading:17390042... | lld:pubmed |
| pubmed-article:17390042 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17390042 | pubmed:articleTitle | Sensitivity to CPT-11 and platinum derivatives of stage II/Dukes' B colorectal cancer with occult neoplastic cells in lymph node sinuses. | lld:pubmed |
| pubmed-article:17390042 | pubmed:affiliation | Department of Surgery, Tokai University Hachioji Hospital, Hachioji, Tokyo 192-0032, Japan. mukai.masaya@hachioji-hosp.tokai.ac.jp | lld:pubmed |
| pubmed-article:17390042 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17390042 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
